Evidence map›Paper›PMID 26147501›Full record

ArticlePloS one2015

Gradual Rarefaction of Hematopoietic Precursors and Atrophy in a Depleted microRNA 29a, b and c Environment.

Lauren Kauffman, Veronica Balatti, Luciano Cascione, Paolo Fadda, Frederick Racke, Ramasamy Santhanam, Stefan Costinean

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Lauren KauffmanComprehensive Cancer Center, The Ohio State University, Columbus, United States of America.
Veronica BalattiComprehensive Cancer Center, The Ohio State University, Columbus, United States of America.
Luciano CascioneInstitute of Oncology Research, Bellinzona, Switzerland.
Paolo FaddaComprehensive Cancer Center, The Ohio State University, Columbus, United States of America.
Frederick RackeDepartment of Pathology, Ohio State Wexner Medical Center, Columbus, United States of America.
Ramasamy SanthanamComprehensive Cancer Center, The Ohio State University, Columbus, United States of America.
Stefan CostineanDepartment of Pathology, Ohio State Wexner Medical Center, Columbus, United States of America.
The Ohio State University · USThe Ohio State University Wexner Medical Center · USInstitute of Oncology Research · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe self-renewing ability of HSCs is fundamental for the maintenance of a pool of bone marrow precursors throughout the life of an individual. The genetic mechanisms underlying such a complex process are still poorly understood. RESULTS AND SIGNIFICANCE: Here, we show that constitutive in vivo deletion of miR29ab1 leads to reduced number of HSCs and that miR29ab1 deficient bone marrow cannot repopulate the bone marrow of irradiated mice. An Affymetrix analysis of the miR29ab1 knockout mice identifies key proteins that could be responsible for this phenotype, as DNMT3a and b. Moreover, our findings reveal that whereas miR29b2c knockout mice do not exhibit any spontaneous abnormality, the double knock out--miR29ab1b2c--has marked generalized atrophy, raising the possibility that the two bi-cistrons might cooperate in order to maintain the stem cell number in general, not only limited to the bone marrow.

Indexed as

AnimalsAtrophyBone Marrow TransplantationHematopoietic Stem CellsLiverMiceMice, KnockoutMicroRNAsPhenotypeSpleenMicroRNAsMIRN29 microRNA, mouse

Identifiers

PMID26147501
PMCPMC4492741
OpenAlexW2233973894

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.